No Data
No Data
【Hong Kong Stock Connect】Ocumension Bio Inc. (01477) postoperative inflammation indication new drug application for market registration accepted by the National Medical Products Administration.
Jingu Financial News | Opregenesis Bio (01477) announced that a new drug OT-502 (DEXYCU, dexamethasone implant) for the treatment of postoperative inflammation indications has recently been accepted for new drug registration by the National Medical Products Administration. OT-502 (DEXYCU, dexamethasone implant) is a single dose sustained-release drug of dexamethasone (a corticosteroid) used to treat post-cataract surgery inflammation.
AuCompass Bio-B (01477.HK) spent 0.086 million Hong Kong dollars to repurchase 0.019 million shares on September 19th.
On September 19th, Oconova Biomedical-B (01477.HK) announced that it repurchased 0.019 million shares for a total cost of 0.086 million Hong Kong dollars.
Ocuvite Vision Bio-B: The new drug OT-1001 approved by the National Medical Products Administration for marketing authorization application.
Oconovis Bio-B (01477) announced that the application for the market registration of OT-1001 (Zhiweitai), a highly selective and potent histamine H-1 receptor antagonist with anti-allergic properties, has recently been approved by the Drug Evaluation Center of the China National Medical Products Administration (CNMPA).
Express News | Ocumension Therapeutics - New Drug Application of Ot-1001 Approved by China Nmpa
OCUMENSION-B: 2024 Interim Report
Ocuvision Bio-B (01477) spent approximately 7.7285 million Hong Kong dollars to repurchase 1.4505 million shares on August 26.
Orchid Optical-B (01477) announced that it will invest approximately 7.7285 million... on August 26, 2024.
No Data
No Data